Pipeline Delivery Deliver our pipeline on time, at the right costs and with the expected returns. Refill the pipeline so that we get a constant flow of new products in future years Portfolio Focus Maximise our revenue by increasing market penetration, focusing on targeted therapeutic sectors within CAP, Equine, FAP and Nutrition Geographical Expansion Leverage our product portfolio into new geographic regions through distribution partners, in-country presence and new country product registrations Acquisition Expand our geographical footprint and/or enhance our product portfolio through acquisition Strategic Enablers Our strategic enablers, Manufacturing and Supply Chain, People and Technology, support the execution of our strategy Pipeline DeliveryOur Progress 2019 Entered into a number of licensing agreements, including a novel canine sedative and an equine gastric product A number of novel and generic registrations in EU, Mexico and rest of world 15 product launches from Le Vet pipeline Our Achievements 2014 Dossiers submitted in USA and EU for a novel canine endocrinology product Pivotal clinical trial commenced for canine endocrinology opportunity Ongoing characterisation studies for canine dermatological and canine ophthalmology products A number of generic and range extension dossiers submitted in EU Osphos® submitted in Australia and Canada 2015 Seven new projects started in Feasibility Two product approvals: Osphos in EU (April 2015) and TAF Spray® (December 2014) Osphos launched in the USA in August 2014 and in the UK in September 2014, with dedicated sales representatives recruited to support the launch TAF Spray launched in several EU countries 2016 Zycortal approved and launched in the USA in March 2016 and in 14 European markets Osphos launched in 17 additional European countries Several FAP approved, notably Phenocillin® and Solamocta® (for turkeys and ducks) launched in Germany and launch planned for 17 other territories 2017 Signed Animal Ethics licensing agreement, and building pipeline of other in-licensing opportunities Vaccines development strategy defined and new opportunities identified Amoxi-Clav tablet development completed A number of minor FAP market authorisations gained 2018 Two further poultry vaccines registered in EU: Avishield® IBH120 and ND B1 Launch of further Amoxi-Clav dose sizes to complete range for the USA market In-licensing of major new products including Redonyl® Ultra, Vetradent® and BioEquin® Progress in co-development licensing opportunities Portfolio Focus Our Progress 2019 Moved key Le Vet products from distributors to Dechra marketing companies to generate significant synergies through retention of full margin and enhancing sales focus Development and launch of Dechra Dog & Cat Anaesthesia App FAP growth accelerating against a backdrop of declining antibiotic markets Our Achievements 2014 Delivered growth in almost all target therapeutic sectors Cardisure® exceptional growth of 32% across European markets, while Comfortan® grew by 40% Brought in house a number of products acquired through Eurovet enabling the Group to retain full margin and enhance sales focus Updated Dechra Online Academy tool, a platform for CPD for all veterinarians 2015 Vetoryl® grew by 24% globally Dechra Academy was updated and launched successfully in 11 countries with 5,000 new users All core therapeutic areas in CAP, including dermatology, as well as Equine growing at double digit in Europe 2016 Double digit growth in key therapeutic areas Roll out of digital technologies progressed to plan, with the implementation of our Learning Management System, Delta, enabling product training to be disseminated to sales representatives 2017 Strong CAP and Equine growth continuing across the Group, FAP returned to growth Increased effective use of CRM tools in EU and NA Expanded sales force effectiveness training Unblocking of distribution channels for Putney products in the US opened up market for enlarged NA business growth 2018 Resolution of Nutrition supply and palatability issues, and launch of refreshed cat diets Strong growth in European FAP following antibiotic product alignment and range additions Leveraging CAP product success to increase penetration across Group Continued growth in Equine, with stronger growth in Europe from market penetration and range additions Geographical Expansion Our Progress 2019 Expanded into Latin America via the acquisition of Laboratorios Vencofarma do Brasil Ltda (Venco) 43 Product registrations across Israel, South Korea, Macau, Macedonia, Malaysia, Malta, Namibia, Serbia, Ukraine, UAE and Zambia ANZ business leveraged by Caledonian bolt-on Our Achievements 2014 Started trading in Italy – the first • greenfield start up since the USA in 2004 Sales office established in Canada Recruiting additional regulatory support to accelerate product registrations in other territories 2015 Strengthening of distributor relationships New start up in Poland Commenced trading from Canadian entity 2016 Regulatory approvals were obtained in several countries such as Brazil, Egypt and Sri Lanka New start up in Austria 2017 Several international product registrations achieved Established Dechra Veterinary Products (DVP) International business Commenced appointment of the DVP International team 2018 Over 80 new country registrations of existing portfolio products Acquisition of RxVet expanded our presence in New Zealand Successful establishment of the DVP International team Development of international registrations strategy and prioritisation plan Acquisition Our Progress 2019 Acquisition and successful integration of Venco Acquisition of trade and assets of Caledonian Holdings Ltd in New Zealand strengthening market position in Equine Our Achievements 2014 Acquisition of trade and assets of PSPC Inc. and PSPC facility in USA Purchase of new Levothyroxine product to be launched in first half of 2015 financial year 2015 Successful integration of the assets of PSPC with sales exceeding expectations Conditional offer for Genera d.d., a Croatian animal health company, announced post year end on 3 August 2015 2016 Three acquisitions completed: Genera, Brovel and Putney Putney integration helped strengthen our USA presence Genera integration on plan, new business structure defined Registration process of Dechra products commenced in Mexico 2017 Successful integration and operation of Genera, Brovel, Putney and Apex Acquisition of Apex, opening up new bridgehead into Australasia and South East Asia Acquisition of 33.0% of Medical Ethics Pty Ltd provides the Group with secure access to novel therapeutic areas/product development 2018 Acquisition and successful integration of RxVet, expanding our presence in New Zealand First full year of Apex Acquisition and successful initial integration of AST Farma and Le Vet, providing transformation in EU Pharmaceuticals’ portfolio and pipeline Strategic Enablers Our Progress 2019 Appointment of additional Non-Executive Director and Group Manufacturing and Supply Director Strengthened Manufacturing Leadership team Investments in manufacturing and packing at Skipton, a new solid dose facility in Zagreb and an upgrade to the sterile facility in Bladel Oracle ERP now embedded and Phase II completed in DVP EU Our Achievements 2014 Significant investments in the liquids, creams and ointments suite, tablet compression machines and the encapsulation production line in Skipton Brought production of Cardisure and Forthyron® in house – improving margin and giving greater flexibility and control over production of these key CAP products €2 million investment in our new enlarged central European distribution centre in Uldum New supplier of Specific pet diets identified and transfer of production started 2015 On time first order delivery to new country operations in Italy and Poland Completed transition of dry diets manufacturing to new third party site Completed investments in Dechra Pharmaceuticals Manufacturing (DPM) to improve yield and capacity Successful FDA pre-approval inspection at Skipton to manufacture Zycortal® Completed implementation of Group Finance Oracle consolidation module Personal Development Review (PDR) rolled out to all Dechra employees 2016 Good progress in our Oracle roll out with DVP US live in April 2016 Commencement of a new Group Intranet platform for improved communication and information sharing with all employees HR Cloud based IT system implemented in 16 countries Sales and Operations Planning (S&OP) process implemented in DVP EU and DPM 2017 Developed new Manufacturing and Supply Chain strategy Ongoing progress in Oracle deployment IT user hardware standardised across the Group 2018 Progress in execution of Manufacturing remodelling strategy, in Zagreb (inbound transfers) and Bladel (FDA) 12 months without a lost time accident Completion of employee engagement survey, providing valuable feedback Successful implementation of the European Oracle project and completion of Hyperion suite previous Strategic Timeline next Chief Executive Officer's Statement